AIM ImmunoTech Inc (AIM)

Currency in USD
3.15
-4.05(-56.25%)
Closed·
Pre Market
3.02-0.13(-4.13%)
·
AIM Scorecard
Full Analysis
Quickly burning through cash
Unusual trading volume
Fair Value
Day's Range
2.923.69
52 wk Range
2.5139.95
Key Statistics
Prev. Close
3.15
Open
3.5
Day's Range
2.92-3.69
52 wk Range
2.51-39.95
Volume
2.68M
Average Volume (3m)
121.61K
1-Year Change
-91.13%
Book Value / Share
-5.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AIM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

AIM ImmunoTech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

AIM ImmunoTech Inc Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Industry
-
Sector
-
Employees
22

Compare AIM to Peers and Sector

Metrics to compare
AIM
Peers
Sector
Relationship
P/E Ratio
−0.2x−4.4x−0.5x
PEG Ratio
0.000.000.00
Price/Book
−0.6x3.1x2.6x
Price / LTM Sales
17.1x9.9x3.2x
Upside (Analyst Target)
-216.8%42.0%
Fair Value Upside
Unlock9.0%6.6%Unlock

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-5.27 / -8.00
Revenue / Forecast
16.00K / --
EPS Revisions
Last 90 days

AIM Income Statement

People Also Watch

3.16
INMB
+8.59%
32.00
BMNR
-8.86%
15.83
SRPT
+14.21%
0.815
WINT
-11.41%
12.2700
ARTL
-11.92%

FAQ

What Stock Exchange Does AIM ImmunoTech Trade On?

AIM ImmunoTech is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for AIM ImmunoTech?

The stock symbol for AIM ImmunoTech is "AIM."

What Is the AIM ImmunoTech Market Cap?

As of today, AIM ImmunoTech market cap is 668.68M.

What Is AIM ImmunoTech's Earnings Per Share (TTM)?

The AIM ImmunoTech EPS (TTM) is -24.84.

From a Technical Analysis Perspective, Is AIM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has AIM ImmunoTech Stock Split?

AIM ImmunoTech has split 0 times.

How Many Employees Does AIM ImmunoTech Have?

AIM ImmunoTech has 22 employees.

What is the current trading status of AIM ImmunoTech (AIM)?

As of 30 Jul 2025, AIM ImmunoTech (AIM) is trading at a price of 3.15, with a previous close of 3.15. The stock has fluctuated within a day range of 2.92 to 3.69, while its 52-week range spans from 2.51 to 39.95.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.